ALLTEST CEA Rapid Test Kits – Carcinoembryonic Antigen (CEA) Cancer Marker Test

The ALLTEST CEA Rapid Test is a professional in vitro diagnostic device designed for the qualitative detection of Carcinoembryonic Antigen (CEA) in whole blood, serum, or plasma. CEA is a well-established tumour marker associated with a range of malignancies, particularly gastrointestinal cancers (including colorectal cancer), lung cancer, and liver cancer.

Carcinoembryonic antigen (CEA) is a blood-based tumor marker primarily used to monitor treatment response and detect recurrence in colorectal cancer patients. While not a diagnostic tool on its own, elevated CEA levels often indicate active or returning disease (especially liver metastasis), with monitoring recommended every 2–3 months post-treatment

This rapid test provides a reliable and efficient solution for oncology monitoring, cancer recurrence detection, and treatment response assessment in clinical settings.

Professional CEA Rapid Test for Clinical & Laboratory Use

The ALLTEST CEA Rapid Test Cassette delivers fast, on-site results in just 5 minutes, enabling healthcare professionals to make timely clinical decisions. It is suitable for use in:

• GP surgeries and health screening programmes
• Hospitals and oncology departments
• Diagnostic laboratories and clinics

With a minimum detection level of 5 ng/mL, this test identifies elevated CEA levels that may indicate tumour presence, progression, or recurrence.

Key Features & Benefits

• Multi-sample compatibility: Works with venous whole blood, serum, plasma, and finger-prick blood
• Rapid results: Clear qualitative results in 5 minutes
• High clinical performance:
• Sensitivity: 98.9%
• Specificity: 99.5%
• Accuracy: 99.3%
• Early indication of recurrence: Helps detect tumour relapse months before clinical symptoms appear
• Simple procedure: Easy-to-use cassette format with minimal training required
• Complete kit: Includes test cassettes, buffer, droppers, and instructions for use

Clinical Significance of CEA Testing

CEA is an oncofetal glycoprotein typically absent in healthy adults but elevated in various cancers. Monitoring CEA levels is widely used for:

• Tracking cancer progression and treatment response
• Post-treatment surveillance and recurrence detection
• Supporting clinical decision-making alongside other diagnostic methods

Persistent or rising CEA levels may indicate residual disease, metastasis, or ineffective therapy, making this test a valuable tool in long-term patient management.

Important Information

• For professional in vitro diagnostic use only
• Intended for use by qualified healthcare professionals under medical supervision
• This is a qualitative test and should not be used as the sole basis for cancer diagnosis
• Results must be interpreted in conjunction with clinical findings and other laboratory tests
• Lancets and additional sample collection materials may be required but are not included